The National Cancer Institute (NCI) is seeking broad input and feedback from sources of expertise and interest in these oncogenic drivers of childhood cancers. This request for information (RFI) is part of a planning effort designed to recognize current research gaps, identify promising opportunities, and develop strategies to accelerate progress in developing therapeutic strategies for successfully targeting these oncogenic proteins.

CI is seeking information that includes, but is not limited to, the following areas:

• The key rate-limiting areas of knowledge that are slowing the development of novel agents targeting pediatric fusion oncoproteins and for which additional focus is needed.
• The highest priority research areas for moving the field forward towards effective novel agents targeting pediatric fusion oncoproteins.
• The essential proficiencies required to better understand the biology of fusion oncoproteins and make progress in identifying effective novel agents to target specific pediatric fusion oncoproteins.
• New technologies not currently being applied in a significant manner to the study of pediatric fusion oncoproteins that may provide important leads in identifying novel ways of targeting these oncogenic drivers.
• Translational bottlenecks and challenges for advancing promising therapeutic agents through late-stage preclinical development toward an Investigational New Drug application and clinical testing.

All responses must be submitted to pedfusiononcoprotein@mail.nih.gov by March 15, 2022.

NOT-CA-22-032